Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Next Previous
Search
Trial Profile

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DB 1312 (Primary) ; Tislelizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BeiGene

Most Recent Events

  • 17 Apr 2025 Addition of 1 arm in treatments Phase 1b: Combination Therapy Dose Expansion. Planned no. of patients changed to 227.Primary endpoint # 5 changed to Phase 1b: Recommended Phase 2 dose (RP2D) of BG-C9074 as monotherapy and in combination with tislelizumab.
  • 17 Apr 2025 Planned number of patients changed from 150 to 227.
  • 17 Apr 2025 Planned End Date changed from 28 Sep 2027 to 15 May 2028.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top